Market Overview:
The global oral solid dosage pharmaceutical formulation market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and growing demand for generic drugs. By type, the immediate release segment is expected to account for the largest share of the global oral solid dosage pharmaceutical formulation market in 2018. By application, hospital pharmacy is expected to account for the largest share of the global oral solid dosage pharmaceutical formulation market in 2018.
Product Definition:
Oral Solid Dosage Pharmaceutical Formulation is a drug formulation that is designed to be taken orally in the form of a solid dosage form, such as a tablet or capsule. Oral Solid Dosage Pharmaceutical Formulation can include salts, esters, and other derivatives of the drug that are intended for oral administration. The purpose of Oral Solid Dosage Pharmaceutical Formulation is to provide an easy-to-administer dosage form that allows for controlled release of the drug over an extended period of time.
Immediate Release:
Immediate release dosage form is a pharmaceutical formulation that delivers the drug to the site of action quickly, thus allowing for more control over drug therapy. The main objective of using an immediate release formulation is to improve patient compliance by reducing extended periods between doses and/or eliminating dose frequency altogether.
The global oral solid dosage pharmaceutical formulation market size was valued at USD 4,65 billion in 2016.
Extended Release:
Extended release dosage is a group of dosage forms that release the drug over an extended period. The most common types are capsules, tablets, and films. In comparison to conventional pharmaceutical formulations, these have more advantages such as reduced nausea and vomiting; improved patient compliance; decreased peak plasma concentration (PCC); increased average plasma concentration (APC); reduced dose frequency; minimal adverse effects; enhanced therapeutic effect/ greater productivity.; etc.
Application Insights:
The drug stores application segment held the largest share of around 60.0% in 2017. The segment is expected to witness significant growth owing to increasing demand for OSSDPs from consumers as well as healthcare professionals. Furthermore, growing preference for OSSDPs over other dosage forms such as tablets and capsules due to their ease of consumption by patients is expected to be a major factor driving the market growth over the forecast period.
The others application segment includes hospital pharmacies, which accounted for a substantial share in 2017 owing to high usage rates of injectable drugs among hospitals and clinics across developing countries including India, China and Brazil due largelyto low cost coupled with efficient healthcare infrastructure in these countries that encourages bulk purchasing from pharmaceutical manufacturers at lower prices than retail pharmacies do.
Regional Analysis:
Europe dominated the global oral solid dosage formulation market in 2017. This can be attributed to growing geriatric population and high prevalence of chronic diseases, such as Parkinson’s disease, epilepsy, and Huntington's disease. In addition, increasing number of prescriptions for these formulations is also expected to drive growth over the forecast period. Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to rising healthcare expenditure in this region coupled with improving economic conditions leading to increased disposable income levels among individuals.
The North American regional market includes countries such as U.S.
Growth Factors:
- Increasing demand for oral solid dosage pharmaceutical formulations due to their benefits over other dosage forms
- Rising prevalence of chronic diseases, which is expected to increase the demand for oral solid dosage pharmaceutical formulations
- Technological advancements in the field of oral solid dosage pharmaceutical formulation that are expected to offer better patient compliance and safety profiles
- Growing focus on research and development activities by players in the oral solid dosage pharmaceutical formulation market that is likely to result in new product launches
- Increasing number of mergers and acquisitions among players operating in the oral solid dosage pharmaceutical formulation market that is likely to lead to consolidation
Scope Of The Report
Report Attributes
Report Details
Report Title
Oral Solid Dosage Pharmaceutical Formulation Market Research Report
By Type
Immediate Release, Extended Release, Others
By Application
Hospital Pharmacy, Retail Pharmacy, Drug Stores, Others
By Companies
AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Merck, Novartis, Pfizer, AbbVie, Boehringer Ingelheim
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
184
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Oral Solid Dosage Pharmaceutical Formulation Market Report Segments:
The global Oral Solid Dosage Pharmaceutical Formulation market is segmented on the basis of:
Types
Immediate Release, Extended Release, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacy, Retail Pharmacy, Drug Stores, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Bristol-Myers Squibb
- Eli Lilly
- Gilead
- Merck
- Novartis
- Pfizer
- AbbVie
- Boehringer Ingelheim
Highlights of The Oral Solid Dosage Pharmaceutical Formulation Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immediate Release
- Extended Release
- Others
- By Application:
- Hospital Pharmacy
- Retail Pharmacy
- Drug Stores
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oral Solid Dosage Pharmaceutical Formulation Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oral solid dosage pharmaceutical formulation is a type of drug delivery system that uses solid oral dosage forms such as tablets, capsules, and powders. This type of delivery system allows for consistent dosing and improved patient compliance. Oral solid dosage pharmaceutical formulations are often more convenient for patients than other types of drug delivery systems, such as injections or patches.
Some of the major companies in the oral solid dosage pharmaceutical formulation market are AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Gilead, Merck, Novartis, Pfizer, AbbVie, Boehringer Ingelheim.
The oral solid dosage pharmaceutical formulation market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oral Solid Dosage Pharmaceutical Formulation Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Oral Solid Dosage Pharmaceutical Formulation Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Oral Solid Dosage Pharmaceutical Formulation Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Oral Solid Dosage Pharmaceutical Formulation Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Oral Solid Dosage Pharmaceutical Formulation Market Size & Forecast, 2020-2028 4.5.1 Oral Solid Dosage Pharmaceutical Formulation Market Size and Y-o-Y Growth 4.5.2 Oral Solid Dosage Pharmaceutical Formulation Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Immediate Release
5.2.2 Extended Release
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital Pharmacy
6.2.2 Retail Pharmacy
6.2.3 Drug Stores
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oral Solid Dosage Pharmaceutical Formulation Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oral Solid Dosage Pharmaceutical Formulation Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Immediate Release
9.6.2 Extended Release
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital Pharmacy
9.10.2 Retail Pharmacy
9.10.3 Drug Stores
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Immediate Release
10.6.2 Extended Release
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital Pharmacy
10.10.2 Retail Pharmacy
10.10.3 Drug Stores
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Immediate Release
11.6.2 Extended Release
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital Pharmacy
11.10.2 Retail Pharmacy
11.10.3 Drug Stores
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Immediate Release
12.6.2 Extended Release
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital Pharmacy
12.10.2 Retail Pharmacy
12.10.3 Drug Stores
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Immediate Release
13.6.2 Extended Release
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital Pharmacy
13.10.2 Retail Pharmacy
13.10.3 Drug Stores
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oral Solid Dosage Pharmaceutical Formulation Market: Competitive Dashboard
14.2 Global Oral Solid Dosage Pharmaceutical Formulation Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Bristol-Myers Squibb
14.3.3 Eli Lilly
14.3.4 Gilead
14.3.5 Merck
14.3.6 Novartis
14.3.7 Pfizer
14.3.8 AbbVie
14.3.9 Boehringer Ingelheim